Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
GEMoaB GmbH is a privately-owned, limited liability biopharmaceutical company based in Dresden, Germany, that is focused on becoming a leading, fully integrated biopharmaceutical company. By focusing on our proprietary next generation ATAC, UniCAR and RevCAR platforms, we intend to discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients with a high unmet medical need.
Founded in 2011 by accomplished and visionary scientists, GEMoaB rapidly grew into a highly ambitious research and development organization with unique and proprietary immunotherapy platforms and a rich pre-clinical and clinical pipeline.
We are working in close cooperation with our sister company Cellex GmbH (based in Dresden and Cologne, Germany), which is responsible for manufacturing UniCAR and RevCAR T-Cells. Cellex is a global leader in the production of allogeneic and autologous cell products. We believe that the synergy between manufacturing expertise, deep science understanding and our innovative platforms is unique and a strong foundation for our research productivity and future success.
Our team is based at the BioInnovation Centre Dresden.
GEMoaB is collaborating with a number of partners committed to the joint development of novel immunotherapies based on our next generation platform technologies. We are open for new clinical or strategic collaborations and also capable to generate ATACs and UniCAR/RevCAR targeting modules based on your target binding moiety of choice. Please contact us for further details.